FDA Adverse Event Death Summary report: N

RESOLUTE ONYX RX

MDR report key: 9995585 · Received April 24, 2020

Report

Report Number
9612164-2020-01682
Event Type
Death
Date Received
April 24, 2020
Date of Event
November 19, 2019
Report Date
April 24, 2020
Manufacturer
MEDTRONIC IRELAND
Product Code
NIQ
PMA / PMN Number
P160043
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IT
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DATE OF EVENT: DATE OF PUBLICATION. JOURNAL ARTICLE TITLE: CORONARY PROTECTION TO PREVENT CORONARY OBSTRUCTION DURING TAVR LITERATURE. REFERENCE: DOI.ORG/10.1016/J.JCIN.2019.11.024. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

THE AIM OF THIS STUDY WAS TO INVESTIGATE THE SAFETY AND EFFICACY OF CORONARY PROTECTION BY PREVENTIVE CORONARY WIRING AND STENTING ACROSS THE CORONARY OSTIA IN PATIENTS AT HIGH RISK FOR CORONARY OBSTRUCTION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR). THIS MULTICENTER, INTERNATIONAL, RETROSPECTIVE STUDY ENROLLED 236 PATIENTS UNDERGOING CP WITH PREEMPTIVE WIRING OF THE CORONARY ARTERIES BETWEEN APRIL 2011 AND FEBRUARY 2019. AMONG 236 PATIENTS UNDERGOING CORONARY PROTECTION WITH PREVENTIVE CORONARY WIRING, 143 HAD EVENTUALLY STENTS IMPLANTED ACROSS THE CORONARY OSTIA AFTER VALVE DEPLOYMENT. RESOLUTE ONYX WERE IMPLANTED IN 23 PATIENTS PARTICIPATING IN THE STUDY. AT 3-YEAR FOLLOW-UP, RATES OF CARDIAC DEATH WERE 7.8% IN PATIENTS RECEIVING STENTS AND 15.7% IN THOSE NOT RECEIVING STENTS. 3-YEAR CLINICAL OUTCOMES OF PATIENTS UNDERGOING CP WITH STENTING ACROSS THE CORONARY OSTIA INCLUDED CARDIAC MORTALITY, MI, STROKE AS WELL AS TWO OCCURRENCES OF STENT THROMBOSIS WHICH WERE FATAL IN BOTH CASES. IT WAS NOTED BOTH CASES OF STENT THROMBOSIS OCCURRED IN PATIENTS RECEIVING SELF-EXPANDING VALVES IMPLANTED IN VALVE-IN-VALVE PROCEDURE FOR FAILED NON-MEDTRONIC BIOPROSTHETIC VALVES. IT WAS STATED THAT THERE WERE 4 CASES OF SUDDEN DEATH, 2 IN PATIENTS RECEIVING STENTS AT 365 AND 703 DAYS AFTER TAVR. IT WAS NOTED THAT THERE WERE 13 DEATHS, 6 CARDIAC DEATHS, 8 MIS, AND 5 STROKES AMONG THE 143 PATIENTS UNDERGOING CORONARY PROTECTION WITH STENT IMPLANTATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
458458 RESOLUTE ONYX RX STENT, CORONARY, DRUG-ELUTING NIQ MEDTRONIC IRELAND

Patients

Seq Age Sex Outcome Treatment
1 80 YR Death| R